Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2573167rdf:typepubmed:Citationlld:pubmed
pubmed-article:2573167lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:2573167lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:2573167lifeskim:mentionsumls-concept:C2607857lld:lifeskim
pubmed-article:2573167pubmed:issue25lld:pubmed
pubmed-article:2573167pubmed:dateCreated1989-12-5lld:pubmed
pubmed-article:2573167pubmed:abstractTextBeta blockers are known to cause reduced exercise performance in hypertensive and healthy subjects. Additive effects of selective blockade of beta-1 and beta-2 receptor subtypes seems to account for the total reduction in exercise capacity observed with non-selective beta-1,2 blockade. The mechanism is as yet undefined. The magnitude of the reduction is dependent of type of exercise and level of fitness. Hemodynamic parameters, substrate delivery to the working muscles, mental factors, and interference with potassium homeostasis may be involved.lld:pubmed
pubmed-article:2573167pubmed:languagenorlld:pubmed
pubmed-article:2573167pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2573167pubmed:citationSubsetIMlld:pubmed
pubmed-article:2573167pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2573167pubmed:statusMEDLINElld:pubmed
pubmed-article:2573167pubmed:monthSeplld:pubmed
pubmed-article:2573167pubmed:issn0029-2001lld:pubmed
pubmed-article:2573167pubmed:authorpubmed-author:KjekshusJJlld:pubmed
pubmed-article:2573167pubmed:authorpubmed-author:DolvaL OLOlld:pubmed
pubmed-article:2573167pubmed:authorpubmed-author:GullestadLLlld:pubmed
pubmed-article:2573167pubmed:authorpubmed-author:SøylandEElld:pubmed
pubmed-article:2573167pubmed:issnTypePrintlld:pubmed
pubmed-article:2573167pubmed:day10lld:pubmed
pubmed-article:2573167pubmed:volume109lld:pubmed
pubmed-article:2573167pubmed:ownerNLMlld:pubmed
pubmed-article:2573167pubmed:authorsCompleteYlld:pubmed
pubmed-article:2573167pubmed:pagination2544-7lld:pubmed
pubmed-article:2573167pubmed:dateRevised2008-7-16lld:pubmed
pubmed-article:2573167pubmed:meshHeadingpubmed-meshheading:2573167-...lld:pubmed
pubmed-article:2573167pubmed:meshHeadingpubmed-meshheading:2573167-...lld:pubmed
pubmed-article:2573167pubmed:meshHeadingpubmed-meshheading:2573167-...lld:pubmed
pubmed-article:2573167pubmed:meshHeadingpubmed-meshheading:2573167-...lld:pubmed
pubmed-article:2573167pubmed:meshHeadingpubmed-meshheading:2573167-...lld:pubmed
pubmed-article:2573167pubmed:meshHeadingpubmed-meshheading:2573167-...lld:pubmed
pubmed-article:2573167pubmed:meshHeadingpubmed-meshheading:2573167-...lld:pubmed
pubmed-article:2573167pubmed:year1989lld:pubmed
pubmed-article:2573167pubmed:articleTitle[Beta blockaders and physical performance. Limiting factors].lld:pubmed
pubmed-article:2573167pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2573167pubmed:publicationTypeEnglish Abstractlld:pubmed